
    
      This single-arm phase II trial enrolled extensive-stage SCLC patients without prior
      systematic chemotherapy or immunity checkpoint inhibitors therapy at Xiangya hospital,
      Central South University from Aug 15, 2018 to Oct 7, 2020.The study was done in accordance
      with the International Conference on Harmonisation good clinical practice guidelines, the
      Declaration of Helsinki, and applicable local regulations with approval from an independent
      ethics committee or institutional review boards.

      Eligible patients were age 18-70 years with histologically confirmed extensive-stage
      small-cell lung cancer as defined according to the staging standard introduced by the
      Veterans Administration Lung Study Group (VALG), measurable according to Response Evaluation
      Criteria in Solid Tumors (RECIST v1.1), and an Eastern Cooperative Oncology Group (ECOG)
      performance-status (PS) score of 0 or 1, who had not received previous systemic treatment for
      extensive-stage small-cell lung cancer and were expected survival time â‰¥3 months. Patients
      with treated asymptomatic central nervous system (CNS) metastases were eligible under some
      circumstance (see the Supplementary Appendix). Key exclusion criteria were a history of mixed
      small cell carcinoma and non-small cell carcinoma and with active central nervous system
      (CNS) metastasis and/or cancerous meningitis during screenings.
    
  